Mallinckrodt Pharmaceuticals Continues Efforts to Fight Medicine Abuse with The Partnership® at Drug

Before you go, we thought you'd like these...
Before you go close icon

Mallinckrodt Pharmaceuticals Continues Efforts to Fight Medicine Abuse with The Partnership® at

Company renews commitment to support The Medicine Abuse Project™ in its second year

ST. LOUIS--(BUSINESS WIRE)-- Mallinckrodt (NYS: MNK) announced today that it will continue its collaboration with The Partnership at for a second year in support of The Medicine Abuse Project. The campaign brings together families, communities, industry, health care professionals, educators, law enforcement and government officials to help save lives by preventing teen medicine abuse. Mallinckrodt is renewing its support as a Gold Sponsor, extending the Company's strong commitment to fighting abuse, diversion, and misuse of powerful pain medications.

"Mallinckrodt is dedicated to providing safe and effective medications for the treatment of patients with pain, and equally committed to collaborating with organizations like The Partnership at to curb diversion, misuse, and abuse," said Mark Trudeau, President and Chief Executive Officer, Mallinckrodt Pharmaceuticals. "Support of The Medicine Abuse Project is one example of our broad engagement to prevent medicine abuse and ensure access only to the patients who need treatment. We think this project has been especially effective, given the range of stakeholders involved - from public health officials to community groups to law enforcement - since collaboration is critical to addressing this vital issue."

"Medicine abuse is one of the most significant and preventable adolescent health problems facing our families today," said Steve Pasierb, President and CEO of The Partnership at "The Partnership is grateful for socially responsible companies like Mallinckrodt whose support has helped us launch The Medicine Abuse Project and mobilize both parents and the public to learn about the problem, talk with their kids about the dangers of misuse and abuse of prescription drugs, and properly monitor, safeguard, and dispose of excess prescription drugs in their homes."

A recent study by The Partnership for found that one in four teens in the U.S. (24 percent) misused or abused a prescription drug at least once in their lifetime, a 33 percent increase since 2008. The Medicine Abuse Project aims to reverse that trend by empowering parents to educate their children on the risks of abusing medicine, as well as safeguarding and properly disposing of unused medications.

The Project's overarching goal by 2017 is to prevent half a million teens from abusing medicine. Phase I of the campaign, launched in September 2012, began raising awareness of the issue by asking stakeholders to take a Pledge against medicine abuse. To date, more than 7,200 people have taken the Pledge. Through media and digital engagement, advocacy, and community outreach efforts, such as National Drug Take-Back Day, the campaign has reached millions of Americans in an effort to achieve its goal. For more information, visit


Mallinckrodt is a leading global specialty pharmaceuticals business that develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents. The Company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 50 countries and distribution in approximately 40 countries. The Company's 2012 revenue totaled $2.1 billion. To learn more about Mallinckrodt, visit

Lynn Phillips, 314-654-3263
Manager, Media Relations
Meredith Fischer, 314-654-6595
Senior Vice President, Communications
John Moten, 314-654-6650
Vice President, Investor Relations

KEYWORDS:   United States  North America  Missouri


The article Mallinckrodt Pharmaceuticals Continues Efforts to Fight Medicine Abuse with The Partnership® at originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading